Design of proteasome inhibitors with oral efficacy in vivo against


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
28 09 2021
Historique:
accepted: 16 08 2021
entrez: 22 9 2021
pubmed: 23 9 2021
medline: 5 10 2021
Statut: ppublish

Résumé

The

Identifiants

pubmed: 34548400
pii: 2107213118
doi: 10.1073/pnas.2107213118
pmc: PMC8488693
pii:
doi:

Substances chimiques

Boron Compounds 0
Proteasome Inhibitors 0
Proteasome Endopeptidase Complex EC 3.4.25.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI152533
Pays : United States
Organisme : NIAID NIH HHS
ID : R33 AI127581
Pays : United States

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

Antimicrob Agents Chemother. 2013 Aug;57(8):3576-84
pubmed: 23689711
Biochem J. 2010 Sep 15;430(3):461-76
pubmed: 20632995
Chem Biol. 2012 Dec 21;19(12):1535-45
pubmed: 23142757
Exp Parasitol. 2007 Mar;115(3):296-300
pubmed: 17087929
Nat Commun. 2018 Sep 18;9(1):3805
pubmed: 30228275
ACS Chem Biol. 2014 Aug 15;9(8):1869-76
pubmed: 24918547
J Med Chem. 2019 Aug 8;62(15):7032-7041
pubmed: 31283222
Clin Chem. 2000 May;46(5):673-83
pubmed: 10794750
Angew Chem Int Ed Engl. 2021 Apr 19;60(17):9279-9283
pubmed: 33433953
J Med Chem. 2018 Nov 21;61(22):10053-10066
pubmed: 30373366
Sci Transl Med. 2019 Sep 18;11(510):
pubmed: 31534021
Cancer Res. 2010 Mar 1;70(5):1970-80
pubmed: 20160034
Bioorg Med Chem Lett. 1998 Feb 17;8(4):333-8
pubmed: 9871680
Nature. 2016 Feb 11;530(7589):233-6
pubmed: 26863983
Science. 2016 Aug 5;353(6299):594-8
pubmed: 27493187
J Med Chem. 2020 Nov 12;63(21):13103-13123
pubmed: 33095579
Antimicrob Agents Chemother. 2009 Oct;53(10):4533-6
pubmed: 19596869
Structure. 2006 Mar;14(3):451-6
pubmed: 16531229
Trends Parasitol. 2017 Sep;33(9):731-743
pubmed: 28688800
Nat Commun. 2018 Aug 17;9(1):3314
pubmed: 30115924
PLoS Pathog. 2019 Jun 6;15(6):e1007722
pubmed: 31170268
Trends Parasitol. 2021 Aug;37(8):709-721
pubmed: 34001441
Malar J. 2008 Sep 24;7:187
pubmed: 18816382
J Am Chem Soc. 2018 Sep 12;140(36):11424-11437
pubmed: 30107725
Malar J. 2017 Jan 13;16(1):26
pubmed: 28086874
PLoS Biol. 2015 Apr 22;13(4):e1002132
pubmed: 25901609
Chem Biol. 2001 Aug;8(8):739-58
pubmed: 11514224
Emerg Infect Dis. 2021 Jan;27(1):294-296
pubmed: 33350925
Chem Biol. 2009 Dec 24;16(12):1278-89
pubmed: 20064438
Proc Natl Acad Sci U S A. 2018 Jul 17;115(29):E6863-E6870
pubmed: 29967165
PLoS One. 2008 May 21;3(5):e2252
pubmed: 18493601
Lancet Infect Dis. 2019 Sep;19(9):952-961
pubmed: 31345710
Malar J. 2015 Nov 05;14:441
pubmed: 26542470
Expert Opin Pharmacother. 2018 Mar;19(4):375-386
pubmed: 29478351
Nat Microbiol. 2019 Nov;4(11):1990-2000
pubmed: 31384003
Mol Cancer Ther. 2006 Dec;5(12):3052-61
pubmed: 17172407
ACS Infect Dis. 2016 Apr 8;2(4):281-293
pubmed: 27275010

Auteurs

Stanley C Xie (SC)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.

Riley D Metcalfe (RD)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.

Hirotake Mizutani (H)

Discovery Strategy and Operations, Takeda Pharmaceuticals International Co., Cambridge, MA 02139.

Tanya Puhalovich (T)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.

Eric Hanssen (E)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Ian Holmes Imaging Centre, Bio21 Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.

Craig J Morton (CJ)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.

Yawei Du (Y)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.

Con Dogovski (C)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.

Shih-Chung Huang (SC)

Discovery Strategy and Operations, Takeda Pharmaceuticals International Co., Cambridge, MA 02139.

Jeffrey Ciavarri (J)

Discovery Strategy and Operations, Takeda Pharmaceuticals International Co., Cambridge, MA 02139.

Paul Hales (P)

Discovery Strategy and Operations, Takeda Pharmaceuticals International Co., Cambridge, MA 02139.

Robert J Griffin (RJ)

Discovery Strategy and Operations, Takeda Pharmaceuticals International Co., Cambridge, MA 02139.

Lawrence H Cohen (LH)

Discovery Strategy and Operations, Takeda Pharmaceuticals International Co., Cambridge, MA 02139.

Bei-Ching Chuang (BC)

Discovery Strategy and Operations, Takeda Pharmaceuticals International Co., Cambridge, MA 02139.

Sergio Wittlin (S)

Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland.
University of Basel, 4003 Basel, Switzerland.

Ioanna Deni (I)

Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY 10032.

Tomas Yeo (T)

Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY 10032.

Kurt E Ward (KE)

Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY 10032.

Daniel C Barry (DC)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.

Boyin Liu (B)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.

David L Gillett (DL)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.

Benigno F Crespo-Fernandez (BF)

Global Health Pharma Research Unit, GSK, 28760 Madrid, Spain.

Sabine Ottilie (S)

Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA 92093.

Nimisha Mittal (N)

Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA 92093.

Alisje Churchyard (A)

Department of Life Sciences, Imperial College London, London SW7 2AZ, United Kingdom.

Daniel Ferguson (D)

Department of Biology and South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio, San Antonio, TX 78249.

Anna Caroline C Aguiar (ACC)

São Carlos Institute of Physics, University of São Paulo, São Carlos 13563-120, Brazil.

Rafael V C Guido (RVC)

São Carlos Institute of Physics, University of São Paulo, São Carlos 13563-120, Brazil.

Jake Baum (J)

Department of Life Sciences, Imperial College London, London SW7 2AZ, United Kingdom.

Kirsten K Hanson (KK)

Department of Biology and South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio, San Antonio, TX 78249.

Elizabeth A Winzeler (EA)

Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA 92093.

Francisco-Javier Gamo (FJ)

Global Health Pharma Research Unit, GSK, 28760 Madrid, Spain.

David A Fidock (DA)

Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, NY 10032.
Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032.

Delphine Baud (D)

Drug Discovery, Medicines for Malaria Venture, 1215 Geneva 15, Switzerland.

Michael W Parker (MW)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Structural Biology, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia.

Stephen Brand (S)

Drug Discovery, Medicines for Malaria Venture, 1215 Geneva 15, Switzerland.

Lawrence R Dick (LR)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Seofon Consulting, Natick, MA 01760.

Michael D W Griffin (MDW)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.

Alexandra E Gould (AE)

Discovery Strategy and Operations, Takeda Pharmaceuticals International Co., Cambridge, MA 02139; ltilley@unimelb.edu.au sandy.gould@takeda.com.

Leann Tilley (L)

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia; ltilley@unimelb.edu.au sandy.gould@takeda.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH